SHARPE
Reported results
- Product revenue, net was $31.0 million for the three months ended September 30, 2026.
- Research and development expenses were $145.7 million for the three months ended September 30, 2026.
- Adjusted R&D expenses (Non-GAAP) were $137.4 million for the three months ended September 30, 2026.
- Selling, general and administrative expenses were $154.1 million for the three months ended September 30, 2026.
- Loss from continuing operations, net of tax was $153.0 million for the three months ended September 30, 2026.
- Adjusted loss from continuing operations, net of tax (Non-GAAP) was $133.4 million for the three months ended September 30, 2026.
Price and volatility reaction
The stock moved +4.6% on the print. No front-expiry chain was on file, so there is no straddle expected move.
| Measure | Value | Basis |
|---|---|---|
| Close before release | 38.88 | 2026-11-06 |
| Close after release | 40.67 | 2026-11-09 |
| Realised move | +4.6% | close to close |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-09 (8-K, Item 2.02). Read the original filing on sec.gov.